Clinical trialNCT01509638CompletedPhase 4Interventional

A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501

SponsorPacira Pharmaceuticals, IncEnrollment47Retraction of Colostomy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Marylise Boutros, M.D.
Cleveland Clinic Florida
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Cleveland Clinic Florida
Weston, Florida, United States
Cleveland Clinic Ohio
Beachwood, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Group 1 Standard of CareGroup 2 EXPAREL

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2012
Primary completion: 31 Oct 2012
Completion: 31 Oct 2012
Last update posted: 6 Mar 2014
Registered enrollment: 47
Registry id: NCT01509638

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.